THQ vs ANNX Comparison

abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies. The fund invests in equity and debt securities of public and private healthcare companies believed by the Fund's Adviser to have potential for above-average growth, and may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, provided these securities comprise 10% or less of Managed Assets.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.